Congenital Cytomegalovirus Infection Clinical Trial
Official title:
Feasibility to Achieve, Before One Month of Age, the Diagnosis of Congenital CMV Diagnosis and the Formal Audiologic Assessment in Newborns Who Failed Newborn Hearing Screening
Universal hearing screening at birth by use of otoacoustic emission (OAE) is now offered in most maternities in France to detect symptomatic hearing impairment at birth but screening of cCMV infection is not coupled with this screening. In this study, the feasibility of achieving before one month of age the diagnosis of congenital CMV diagnosis and as well as the confirmation of hearing loss in newborns who failed newborn hearing screening will be tested.
Congenital cytomegalovirus (cCMV) is the most frequent congenital infection in France. Around 90% of cCMV infected infants are asymptomatic at birth, of whom 7 to 20% develop sensorineural hearing loss (SNHL). cCMV explains at least 10% of all hearing loss cases in young children. Early antiviral treatment (implemented before 1 month of age) with ganciclovir or valganciclovir can improve hearing outcome. In the absence of universal screening, cCMV remains largely undetected because most infected neonates are asymptomatic or have non-specific symptoms. When symptoms become apparent or develop, it may be too late for confirmation that the infection is of congenital origin becausediagnosis of congenital infection is based on the detection of CMV in samples collected within 2 to 3 weeks after birth. The presence of CMV in samples collected after this time may represent postnatal infection which does not carry the risk of hearing loss or neurodevelopmental sequelae. Universal hearing screening at birth by use of otoacoustic emission (OAE) is now offered in most maternities in France to detect symptomatic hearing impairment at birth but screening of cCMV infection is not coupled with this screening. In this study, the feasibility of achieving before one month of age the diagnosis of congenital CMV diagnosis and as well as the confirmation of hearing loss in newborns who failed newborn hearing screening will be tested. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01923636 -
Prognostic Value of Neonatal Markers for the Development of Neurosensorial Sequelae in Children Infected by Cytomegalovirus in Utero
|
N/A | |
| Recruiting |
NCT03973359 -
Epidemiology and Prevention of Congenital HCMV in Immune Mothers. Congenital HCMV Infection Lombardy
|
N/A | |
| Completed |
NCT02005822 -
Congenital Cytomegalovirus: Efficacy of Antiviral Treatment
|
Phase 3 | |
| Withdrawn |
NCT02594566 -
Safety, Tolerability, and Immunogenicity of a Cytomegalovirus DNA Vaccine
|
Phase 1 | |
| Completed |
NCT02351102 -
Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT05170269 -
Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion)
|
Phase 3 | |
| Not yet recruiting |
NCT06118515 -
A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus
|
Phase 1 | |
| Completed |
NCT02782988 -
Assesment of Olfactory Disorders and Performance of a New Olfactory Test in Children With Congenital CMV
|
||
| Completed |
NCT02645396 -
A Cohort Study of Congenital Cytomegalovirus Infection Among Pregnant Women and Their Newborns in China
|
||
| Terminated |
NCT01655212 -
Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial
|
Phase 3 | |
| Completed |
NCT02710864 -
A Cross-sectional Study of Congenital Cytomegalovirus Infection in Newborns in China
|
||
| Completed |
NCT05754879 -
Diagnosis of Congenital Cytomegalovirus Infection in Newborn With Particular Risk
|
||
| Terminated |
NCT03301415 -
Asymptomatic Congenital CMV Treatment
|
Phase 2 | |
| Completed |
NCT01376778 -
A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)
|
Phase 3 |